Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Atorvastatin (Lipitor) and Rosuvastatin (Crestor) — clinical data, side effects, and patient experiences.
Lipitor · HMG-CoA Reductase Inhibitor (Statin)
How it works
Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL-cholesterol ...
Approved for
Crestor · HMG-CoA Reductase Inhibitor (Statin)
How it works
Competitively inhibits HMG-CoA reductase with high affinity. More hydrophilic than atorvastatin, with greater LDL-C lowering potency on a milligram basis.
Approved for
Estimated frequency (%) based on clinical trial data
Based on 15 Reddit discussions
Atorvastatin
7%
positive
15 threads
Rosuvastatin
0%
positive
0 threads
% of discussions mentioning each side effect
Based on 2 verified patient reviews
No data yet
No data yet
Avg. Duration
36 months
100% still taking
Avg. Duration
24 months
100% still taking
Both Atorvastatin and Rosuvastatin belong to the HMG-CoA Reductase Inhibitor (Statin) class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. Atorvastatin has a half-life of 14 hours, compared to 19 hours for Rosuvastatin. A longer half-life may allow for less frequent dosing but can also mean side effects persist longer.
Both medications are approved for Hyperlipidemia, Primary prevention of cardiovascular disease. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
Atorvastatin has an average efficacy rating of 9.0/10 and tolerability of 7.0/10 across 1 patient review. Rosuvastatin has an average efficacy rating of 10.0/10 and tolerability of 8.0/10 across 1 patient review. Patient-reported outcomes provide real-world context beyond clinical trials, though individual responses to medication vary significantly..
Atorvastatin carries 3 FDA warnings. Rosuvastatin carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
There is 1 clinical study directly comparing Atorvastatin and Rosuvastatin. Head-to-head trial data provides the strongest evidence for comparative effectiveness, though study design, endpoints, and patient populations should be considered when interpreting results.
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.